
Utilizing ECG to Stratify SCD Risk in CHD Patients with LVEF>35%

Min Soo Cho Asan Medical Center University of Ulan, College of Medicine










- 76/M
- Recent infarction with LVEF 42%
- Does the patient require ICD?





Why LVEF >35% important?



Should be the priority for VT/VF risk assessment

- Highest number of those at risk of VT/VF
- Currently non-protected by guideline based on LVEF value






Current risk stratification

Meta analysis for LGE

MUSTT and MADIT trial

		- ···					
1.1.2 Studies With Nonis			myopa				
Assomull (17)	5	35	2	66	2.9%	5.33 [0.98, 29.08	8]
lles (18)	9	31	0	30	1.0%	25.76 [1.42, 465.9	9]
Leyva (19)	3	20	0	77	0.9%	31.00 [1.53, 627.8	1]
Gulati (11)	42	142	23	330	27.2%	5.61 [3.21, 9.7	8]
Neilan (20)	34	81	3	81	5.5%	18.81 [5.47, 64.6	5]
Muller (21)	16	94	4	91	6.5%	4.46 [1.43, 13.9	21
Perazzolo-Marra (22)	17	76	5	61	7.5%	3.23 [1.12, 9.3	31
Masci (23)	6	61	2	167	3.2%	9.00 [1.76, 45.9	
Subtotal (95% CI)		540		903	54.6%	6.27 [4.15, 9.4]	
Total Events	132		39			• *	-
Heterogeneity: Tau ² = 0.01	; Chi ² =	7.26, d	f = 7 (P	= 0.40); $I^2 = 4\%$	6	
Test for Overall Effect: Z =	8.72 (P	< 0.000)))))				
			,				
1.2.2 Studies With Mean EF	>30%						
Assomull (17)	5	35	2	66	2.9%	5.33 [0.98, 29.08]	2006
Klem (10)	21	84	4	53	6.6%	4.08 [1.32, 12.67]	2012
Gulati (11)	42	142	23	330	27.2%	5.61 [3.21, 9.78]	2013
Muller (21)	16	94	4	91	6.5%	4.46 [1.43, 13.92]	2013
Demirel (16)	27	62	7	32	8.8%	2.76 [1.04, 7.32]	2014
Almehmadi (27)	45	248	4	70	7.5%	3.66 [1.27, 10.55]	2014
Masci (23)	6	61	2	167	3.2%	9.00 [1.76, 45.90]	2014
Perazzolo-Marra (22)	17	76	5	61	7.5%	3.23 [1.12, 9.33]	2014
Subtotal (95% CI)		802		870	70.0%	4.48 [3.17, 6.33]	
Total Events	179		51				
Hotorogonoitu: Tou? - 0.00: C	hi2 - 0.05	df - 7 /	B - 0.00)	12 - 00	/		

```
Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 2.85, df = 7 (P = 0.90); l^2 = 0\%
Test for Overall Effect: Z = 8.48 (P < 0.00001)
```



LGE on MRIEPS in MUSTT trial

Risk assessment based on the ECGs were not well evaluated




'J'Am Coll Cardiol Img2016;9:1046 _{லாஷா} Am J Cardiol 2000;86:1214

Technique Conclusion Left ventricular ejection fraction (LVEF) Low LVEF is a well-demonstrated risk factor for SCD. Although low LVEF has been effectively used to select high-risk patients for application of therapy to prevent sudden arrhythmic death, LVEF has limited sensitivity: the majority of SCDs occur in patients with more preserved LVEF. Electrocardiogram (ECG) QRS duration Most retrospective analyses show increased QRS duration is likely a risk factor for SCD. Clinical utility to guide selection of therapy has not been tested. QT interval and QT dispersion Some retrospective analyses data show that abnormalities in cardiac repolarization are risk factors for SCD. Clinical utility to guide selection of therapy has not yet been tested. Signal-averaged ECG (SAECG) An abnormal SAECG is likely a risk factor for SCD, based predominantly on prospective analyses. Clinical utility to guide selection of therapy has been tested, but not yet demonstrated. Short-term heart rate variability (HRV) Limited data link impaired short-term HRV to increased risk for SCD. Clinical utility to guide selection of therapy has not yet been tested. Long-term ambulatory ECG recording (Holter) Ventricular ectopy and NSVT The presence of ventricular arrhythmias (VPBs, NSVT) on Holter monitoring is a well-demonstrated risk factor for SCD. In some populations, the presence of NSVT has been effectively used to select high-risk patients for application of therapy to prevent sudden arrhythmic death. This may also have limited sensitivity. Long-term HRV Low HRV is a risk factor for mortality, but likely is not specific for SCD. Clinical utility to guide selection of therapy has been tested, but not demonstrated. Heart rate turbulence Emerging data show that abnormal heart rate turbulence is a likely risk factor for SCD. Clinical utility to guide selection of therapy has been tested, but not yet demonstrated. Exercise test/functional status Exercise capacity and NYHA class Increasing severity of heart failure is a likely risk factor for SCD, although it may be more predictive of risk for progressive pump failure. Clinical utility to guide selection of therapy has not yet been tested. Heart rate recovery and recovery ventricular Limited data show that low heart rate recovery and ventricular ectopy during recovery are risk factors for SCD. ectopy Clinical utility to guide selection of therapy has not yet been tested. T-wave alternans A moderate amount of prospective data suggests that abnormal T-wave alternans is a risk factor for SCD. Clinical utility to guide selection of therapy has been evaluated, but the results to date are inconsistent. Baroreceptor sensitivity (BRS) A moderate amount of data suggests that low BRS is a risk factor for SCD. Clinical utility to guide selection of therapy has not yet been tested.


Table. Summary of Noninvasive Risk-Stratification Techniques for Identifying Patients With Coronary Artery Disease Who Are At Risk for Sudden Cardiac Death (SCD)








QRS duration






0

Asan Medical Cente

0.5 1.0 1.5 2.0 2.5

3.0




Pain FREE Rx II

QRS Cutoff (ms)	False Positives (n)	True Positives (n)	True Negatives (n)	False Negatives (n)	Sensitivity (%)	Specificity (%)	Positive Predictive Value (%)	Negative Predictive Value (%)
80	303	90	33	5	95	10	23	87
90	271	82	65	13	86	19	23	83
100	198	54	138	41	57	41	21	77
110	168	46	168	49	48	50	21	77
120	108	32	228	63	34	68	23	78
130	92	26	244	69	27	73	22	78
140	56	18	280	77	19	83	24	78
150	43	17	293	78	18	87	28	79
160	13	8	323	87	8	96	38	79
170	12	6	324	89	6	96	33	78
180	2	2	334	93	2	99	50	78
190	1	1	335	94	1	99	50	78


There is little evidence that increased QRS duration associated with an increased SCD Predictive value of QRS duration itself was limited







QT interval & QT dispersion



- QT dispersion = QTmax QTmin
- Non-invasive measurement of inhomogeneity in ventricular repolarization






J Arrhythmia 2006; 22: 209

QT dispersion

AIREX sub-study

VA registry



	Survivors (n=320)	Deceased (n=181)	P value		ıs
Mean QT (ms)	382.0 ± 44.7	385.3 ± 44.9	0.42		
Mean QTc (ms) QT dispersion (ms)	431.8 ± 33.4 82.7 ± 34.3	447.2 ± 40.2 92.0 ± 38.5	<0.001 0.005	B 0.5 - B 0.	
QTc dispersion (ms)	93.1 ± 35.9	105.7 ± 42.7	<0.001		
	Patients without bundle branch block n=467	Patients with bundle branch block n=34		¹ / ₂ ¹ /	
Mean QT (ms)	381.8 ± 43.6	402.1 ± 55.8	0.01	0.1 - 140 123 86 42 4 140 107 80 26 5 0.0	٤
Mean QTc (ms) QT dispersion (ms)	$ \begin{array}{r} 361 & 6 \pm 45 & 6 \\ 435 & 1 \pm 35 & 5 \\ 85 & 6 \pm 35 & 7 \end{array} $	469.1 ± 39.3 91.6 ± 40.8	<0.001 <0.001 0.41	0 10 20 30 40 50 60 70 80 0 10 20 30 40 50 60 70 Months follow-up	0
QT dispersion (mb)	000 - 00 /)1 0 ± 10 0	• ••		

Mean \pm SD.


Relationship between prolonged QT interval and QT dispersion to the SCD showed varying results

- Inter-observer variability or wide overlaps in QT measurement
- Genetic and racial factors may also relevant





QRS fragmentation



Additional R wave (R') or notching in the nadir of S, notching of R, more than one R' (fragmentation)




Represent the conduction delay caused by regional myocardial scar



QRS fragmentation

Clinical outcomes



LV aneurysm


Total Number of Patients Studied (N = 330)	LVA Present (N = 110)	LVA Absent (N = 220) ^a
Fragmented QRS present	55	11
(N = 66)	(True-positive)	(False-positive)
Fragmented QRS absent	55	209
(N = 264)	(False-negative)	(True-negative)

PPV 83.3%; NPV 79.2%


		Risk ratio		Risk ratio
Study or subgroup	Weight	M-H, random, 95% CI	Year	M–H, random, 95% CI
Das 2008	12.0%	1.98 (1.57, 2.50)	2008	-
Cheema 2010	11.8%	0.82 (0.62, 1.08)	2010	-
Das 2010	9.1%	1.64 (0.69, 3.88)	2010	+
Sha 2011	4.0%	2.84 (0.35, 23.17)	2011	
Rickard 2011	11.5%	1.20 (0.83, 1.72)	2011	+
Forleo 2011	11.1%	1.28 (0.80, 2.07)	2011	+-
Pei 2012	12.1%	4.34 (3.75, 5.01)	2012	-
Yan 2012	4.1%	0.28 (0.04, 2.15)	2012	
Ozcan 2013	10.3%	3.87 (2.03, 7.36)	2013	
Ahn 2013	3.4%	1.25 (0.12, 13.20)	2013	
Lorgis 2013	10.6%	1.94 (1.08, 3.48)	2013	
Total (95% CI)	100.0%	1.71 (1.02, 2.85)		•
Total events				
Heterogeneity: $\tau^2 = 0$.	56; $\chi^2 = 157$	7.88, df=10 (P<0.00001); <i>l</i> ² =94%	
Test for overall effect				0.01 0.1 1 10 100
				Rejects fQRS Favours fQRS


- fQRS is a strong independent predictor of major cardiovascular events
- It also associated with LV aneurysm, prior myocardial infarction, or perfusion abnormality after revascularization





QRS scoring






Asan Medical Cente

- ECG scoring to quantify myocardial scar
- Quantification of substrate for the reentrant tachycardia
- SCD-HeFT population
 - Scar presence = LVEF < 25%




Heart Rhythm 2011;8:38


Signal-averaged ECG



- Identify the late potential using amplified high-resolution ECG
- Associated with mortality, cardiac arrest, and VT inducibility
- Good NPV but low PPV
- Prognostic value has become less clear in PCI era








FINGER	EF ≤ 35% (<i>n</i> = 226)		EF > 35% (<i>n</i> = 1904)		
registry	SCD (n = 17)		SCD (<i>n</i> = 35)		
	HR (95% Cl)	P-value	HR (95% Cl)	P-value	
Multivariable analysis ^a					
NsVT	2.1 (0.7-6.7)	0.2010	3.5 (1.5-8.2)	0.0021	
VPCs > 10/h	1.9 (0.7-5.4)	0.3322	1.2 (0.5-3.1)	0.7345	
SDNN < 70 ms	1.3 (0.5-3.4)	0.6148	1.5 (0.7-3.4)	0.3074	
SDNN (continuous)	1.00 (0.98-1.02)	0.7733	0.99 (0.97-1.00)	0.0292	
ln VLF < 5.3	0.8 (0.2-3.9)	0.7996	2.7 (1.0-7.1)	0.0505	
ln VLF (continuous)	1.26 (0.75-2.11)	0.3726	0.62 (0.46-0.82)	0.0008	
ln LF < 3.85	0.7 (0.2-3.4)	0.6979	2.6 (0.9-7.9)	0.0826	
ln LF (continuous)	1.24 (0.79-1.95)	0.3450	0.63 (0.50-0.81)	0.0002	
TS (≤2.5 ms/RRI)	1.0 (0.4-2.1)	0.9310	4.7 (2.3-9.8)	0.0001	
TS (continuous)	1.04 (0.89-1.21)	0.6418	0.77 (0.67-0.88)	0.0001	
DFA ($\alpha_1 < 0.75$)	1.0 (0.4-2.7)	0.5123	2.7 (1.3-5.7)	0.0088	
DFA (continuous)	1.53 (0.13-17.4)	0.7317	0.26 (0.06-1.10)	0.0673	
$QRS \ge 120 \text{ ms}$	0.9 (0.3-3.1)	0.9843	3.2 (1.4-7.3)	0.0039	
QRS (continuous)	1.00 (0.98-1.02)	1.0000	1.00 (1.00-1.00)	0.4845	

CHS study



- Non-sustained VT or frequent PVCs are useful predictor in patients with LVEF > 35%
- Routine use for assessing SCD risk is limited for low sensitivity and specificity







Non-sustained VT

MADIT trial

Methods Over the course of five years, 196 patients in New York Heart Association functional class I, II, or III with prior myocardial infarction; a left ventricular ejection fraction ≤ 0.35 ; a documented episode of asymptomatic unsustained ventricular tachycardia; and inducible, nonsuppressible ventricular tachyarrhythmia on electrophysiologic study were randomly assigned to receive an implanted defibrillator (n=95) or conventional medical therapy (n=101). We used a two-sided sequential design with death from any cause as the end point.




PLATO sub-study



- MADIT trial demonstrate the NSVT or inducible VT benefited from the ICD therapy
 - PLATO trial sub-study, 2,866 patients with 7 –day Holter at acute stage and convalescent phase (30 days)



HRV



	Relative risk (95% CI)	р
Model including BRS		
LVEF		
35–50%	2.1 (0.90-4.69)	0.08
<35%	4.7 (2.04-10.9)	0.0003
BRS (ms per mm Hg)		
3.0-6.1	1.7 (0.81-3.69)	0.15
<3.0	2.8 (1.24-6.16)	0.01
≥10 VPC/h	1.8 (0.94-3.46)	0.07
Model including SDNN		
LVEF		
35–50%	1.9 (0.87-4.49)	0.10
<35%	3.9 (1.69-9.25)	0.001
SDNN (ms)		
70–105	1.9 (0.86-4.04)	0.11
<70	3.2 (1.42-7.36)	0.005
≥10 VPC/h	1.8 (0.97-3.50)	0.06

Figure 1: Kaplan-Meier survival curves for total cardiac mortality according to BRS, SDNN, and their combination p value refers to differences in event rates between subgroups.

Table 4: Multivariate Cox proportional-regression models

- Monitoring Short (2-30 min) or longer (24 hour) periods
- Decreased HRV associated with increased arrhythmia and mortality
- Use of HRV to predict SCD risk in patients with CAD is limited
 - Effect of ischemia and PCI on HRV
 - Effect of age, gender, medications (BB or ACEi)
 - Atrial fibrillation









PATIENT POPULATION

Patients aged 18 to 80 years were eligible if they had recently had a myocardial infarction (6 to 40 days previously) and if they had a left ventricular ejection fraction of 0.35 or less, as assessed by angiography, radionuclide scanning, or echocardiography. Patients also had to have a standard deviation of normal-to-normal RR intervals of 70 msec or less or a mean RR interval of 750 msec or less (heart rate, 80 beats per minute or greater) over a 24-hour period,8-12 as assessed by 24-hour Holter monitoring performed at least three days after the infarction.






- Impaired autonomic function are associated with increased mortality
- ICD implantation failed to demonstrate the benefit in patients with LVEF + HRV patients

Reduced death from arrhythmia which was offset by non-arrhythmic death



N Engl J Med 2004;351:2481

HR turbulence



- Short term fluctuation in sinus CL after VPCs
- Powerful predictor of SCD in patients with CAD
- Compensatory Mx to PVC induced CO↓ + low SBP
 - \rightarrow baroreceptor activation

an Medical Cente


- Affected by age, medication, LV function, revascularization
- Not tested in the prospective data



T wave alternans

REVINE and FINCAVAS

ABCD study



Dispersion of repolarization

an Medical Cente

- Increased TWA associated with SCD
- MTWA achieved 1-year PPV 9% and NPV 95%, comparable to EPS
 - Useful for identifying low-risk patients.

Clin Cardiol 2011;34:466 J Am Coll Cardiol 2009;53:1130 J Am Coll Cardiol 2009;53:471



Current status




EHRA POSITION PAPER

European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population

Jens Cosedis Nielsen (EHRA Chair)¹*, Yenn-Jiang Lin (APHRS Co-Chair)², Marcio Jansen de Oliveira Figueiredo (LAHRS Co-Chair)³, Alireza Sepehri Shamloo⁴, Alberto Alfie⁵, Serge Boveda⁶, Nikolaos Dagres⁴, Dario Di Toro⁷, Lee L. Eckhardt⁸, Kenneth Ellenbogen⁹, Carina Hardy¹⁰, Takanori Ikeda¹¹, Aparna Jaswal¹², Elizabeth Kaufman¹³, Andrew Krahn¹⁴, Kengo Kusano¹⁵, Valentina Kutyifa^{16,17}, Han S. Lim^{18,19}, Gregory Y.H. Lip^{20,21}, Santiago Nava-Townsend²², Hui-Nam Pak²³, Gerardo Rodríguez Diez²⁴, William Sauer²⁵, Anil Saxena²⁶, Jesper Hastrup Svendsen^{27,28}, Diego Vanegas²⁹, Marmar Vaseghi³⁰, Arthur Wilde³¹, and T. Jared Bunch (HRS Co-Chair)³², ESC Scientific Document Group: Alfred E. Buxton³³, Gonzalo Calvimontes³⁴, Tze-Fan Chao², Lars Eckardt³⁵, Heidi Estner³⁶, Anne M. Gillis³⁷, Rodrigo Isa³⁸, Josef Kautzner³⁹, Philippe Maury⁴⁰, Joshua D. Moss⁴¹, Gi-Byung Nam⁴², Brian Olshansky⁴³, Luis Fernando Pava Molano⁴⁴, Mauricio Pimentel⁴⁵. Mukund Prabhu⁴⁶, Wendy S. Tzou⁴⁷, Philipp Sommer⁴⁸, Janice Swampillai⁴⁹, Alejandro Vidal⁵⁰, Thomas Deneke (Reviewer Coordinator)⁵¹, Gerhard Hindricks⁴, and Christophe Leclercq (ESC-CPG representative)⁵²



















Limitations of ECG parameters



- ECG parameters are ubiquitous in patients with ischemic cardiomyopathy
- Generally good NPV, but poor PPV
- ECG is big-picture of myocardial depolarization and repolarization
- Lack of prospective studies with intervention





ECG-Based Test	Advantages	Disadvantages/Limitations	Practical Value for Risk Stratification
12-lead ECG	Cheap, quick and easy to perform; can be obtained serially at each follow-up visit to reassess risk; large databases can be generated and analyzed retrospectively/ prospectively	Many abnormal parameters are markers of increased mortality, rather than specifically SCD; low positive predictive and negative predictive accuracies; subject to interobserver variability (unless automated software is used); considerable overlap in some parameters between healthy subjects and patients	Remains a standard investigation in patients with CAD; low positive and negative predictive accuracies for SCD limit its practical use in risk stratification and selection of ICD candidates
Signal-averaged ECG	Easy and quick to perform; high negative predictive accuracy; can be used in patients with AF	Low positive predictive accuracy; numerous negative studies, especially in current era of interventional cardiology; better at predicting risk of VT than VF; normal standards for patients with bundle branch block or paced rhythm have not been established	Improved risk stratification when used in combination with other tests; probably more useful in identifying low-risk patients; not useful alone for risk stratification
Standard 24-hr Holter	Provides information on other arrhythmias in patients with CAD (eg, AF, heart block); standard test, easy to perform; can be used in patients in AF or paced rhythms	Low sensitivity and specificity	Most promising use is in combination with other parameters (eg, HRV and HRT) obtained from Holter recordings; not useful alone for risk stratification
Heart rate variability	Can be automatically recorded with standard Holter (using additional software); short (2–30 min) and longer (24 h) measurements are possible	Cannot be reliably assessed in patients with AF or frequent PVCs Influenced by a number of factors (eg, age, medication); may be affected by functional state of sinus node; short-term measurements in risk prediction have not been well tested; no consensus on which parameters of HRV or method of assessment is best	Current practical use for risk stratification is limited as a consensus opinion on which parameters of HRV to record and which method of assessing HRV is required
Heart rate turbulence	Value in risk prediction post-AMI supported by several recent large-scale prospective studies; provides prognostic information in patients with normal and impaired LVEF	Optimal time post-AMI to perform the test has not been established; can only be performed in patients in SR with a significant number of PVCs; use in patients with CAD and no history of AMI not well established	A promising test for risk prediction that can be used with other Holter-based measurements; limited practical use at present in the absence of clear guidelines for risk stratification
T-wave alternans	Easy to perform; can use existing equipment or modification of equipment; high negative predictive accuracy	Can only be used in patients in SR; "clean" ECG trace required (difficult to obtain during exercise); indeterminate result if target heart rate not achieved during exercise; low positive predictive accuracy	Useful in risk stratifying patients with impaired and preserved LVEF; useful role in determining which patients are unlikely to benefit from ICD insertion; improved risk stratification when used in combination with other tests; clear guidelines awaited for practical use for risk stratification



.....

Abbreviations: AF, atrial fibrillation; AMI, acute myocardial infarction; CAD, coronary artery disease; ECG, electrocardiogram; HRT, heart rate turbulence; HRV, heart rate variability; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; PVC, premature ventricular complex; SCD, sudden cardiac death; SR, sinus rhythm; VF, ventricular fibrillation; VT, ventricular tachycardia.


Coronary angiography



- NSTEMI with congestive heart failure
- Proceed urgent CABG

















.....



Post-procedure ECG



Summary

- CAD with EF>35% are large group of patients unprotected by current guideline
- Several parameters provide prognostic information, but their sole use in predicting SCD is limited
- ECGs are still useful for clinicians
 - Markers of significant LV dysfunction
 - Perform additional investigations to refine the risk of SCD
- Future studies for the better refinement of ECG predictors are required



